Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | VCP | P55072 | 14/20 | 0.46 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.41 |
| ▸ | KDM1A | O60341 | 2/20 | 0.40 |
| ▸ | EHMT2 | Q96KQ7 | 2/20 | 0.40 |
| ▸ | RCOR1 | Q9UKL0 | 2/20 | 0.40 |
| ▸ | FLT3 | P36888 | 1/20 | 0.40 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.38 |
| ▸ | TOP2A | P11388 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8899747 | 0.95 | VCP (0.47) | VCPSLC2A1 | |
| SCHEMBL8900938 | 0.89 | SLC2A1 (0.44) | SLC2A1KDM1AEHMT2RCOR1FLT3 | |
| SCHEMBL8911894 | 0.88 | VCP (0.48) | VCPSLC2A1KDM1AEHMT2RCOR1 | |
| SCHEMBL8890072 | 0.85 | POLB (0.51) | VCPSLC2A1FLT3TOP2A | |
| SCHEMBL8899767 | 0.84 | PRKCQ (0.42) | VCPSLC2A1KDM1AEHMT2RCOR1 | |
| SCHEMBL8891551 | 0.81 | VCP (0.54) | VCP | |
| Hydrochloric Acid SCHEMBL8899106 | 0.80 | VCP (0.53) | VCP | |
| SCHEMBL8898697 | 0.79 | VCP (0.46) | VCPFLT3 | |
| SCHEMBL8911900 | 0.76 | KDM1A (0.43) | SLC2A1KDM1AEHMT2RCOR1TOP2A | |
| SCHEMBL8899135 | 0.76 | TRIM58 (0.53) | VCPSLC2A1KDM1AEHMT2RCOR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-1997020823-A2 | 2-AMINO QUINAZOLINE DERIVATIVES AS NPY RECEPTOR ANTAGONISTS | NOVARTIS AG (CH) | 1997-06-12 | — | — | WO | claimed |
| WO-1997020823-A2 | 2-AMINO QUINAZOLINE DERIVATIVES AS NPY RECEPTOR ANTAGONISTS | NOVARTIS AG (CH) | 1997-06-12 | — | — | WO | disclosed |